These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 19525681

  • 21. [Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
    Quante M, Pauschert R, Gogarten W.
    Z Orthop Unfall; 2010 Sep; 148(5):532-41. PubMed ID: 20135622
    [Abstract] [Full Text] [Related]

  • 22. [Rivaroxaban in the prevention and treatment of thromboembolic disorders].
    Helbing T, Bode C, Moser M.
    Hamostaseologie; 2012 Sep; 32(3):195-202. PubMed ID: 22777255
    [Abstract] [Full Text] [Related]

  • 23. [Summary and perspectives. Rivaroxaban].
    Albaladejo P.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [Abstract] [Full Text] [Related]

  • 24. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP.
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [Abstract] [Full Text] [Related]

  • 25. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B, Faille D, Ajzenberg N.
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [Abstract] [Full Text] [Related]

  • 26. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC.
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [Abstract] [Full Text] [Related]

  • 29. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR.
    J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
    [Abstract] [Full Text] [Related]

  • 30. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
    Saxer F, Dick W.
    Z Orthop Unfall; 2010 Jan; 148(1):26-30. PubMed ID: 20135590
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Rivaroxaban: practical considerations for ensuring safety and efficacy.
    Smythe MA, Fanikos J, Gulseth MP, Wittkowsky AK, Spinler SA, Dager WE, Nutescu EA.
    Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
    [Abstract] [Full Text] [Related]

  • 37. Rivaroxaban: an oral direct inhibitor of factor Xa.
    Gulseth MP, Michaud J, Nutescu EA.
    Am J Health Syst Pharm; 2008 Aug 15; 65(16):1520-9. PubMed ID: 18693206
    [Abstract] [Full Text] [Related]

  • 38. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD, EXPERT Study Group.
    Thromb Haemost; 2009 Jan 15; 101(1):68-76. PubMed ID: 19132191
    [Abstract] [Full Text] [Related]

  • 39. Rivaroxaban, the first oral, direct factor Xa inhibitor.
    Fassiadis N.
    Expert Opin Pharmacother; 2009 Dec 15; 10(18):2945-6. PubMed ID: 19925048
    [Abstract] [Full Text] [Related]

  • 40. Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
    Perzborn E.
    Hamostaseologie; 2009 Aug 15; 29(3):260-7. PubMed ID: 19644596
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.